Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: GlobalData
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals Ltd announces FDA assigns Sept. 29, Prescription Drug User Fee Act Goal Date for RELISTOR

Monday, 11 Aug 2014 07:00am EDT 

Salix Pharmaceuticals Ltd:Food and Drug Administration (FDA or Agency) has informed Salix that supplemental New Drug Application (sNDA) for RELISTOR(methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml.Says for treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain has been assigned user fee goal date of Sept. 29.